Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #576 - VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D)
Brief Summary: The overall purpose is to determine research based 'next-steps' for outpatients with major depressive disorder who have not had satisfactory outcomes to standard 'first-step' treatments. The primary objective is to compare the acute (up to 12 weeks) treatment effectiveness of augmenting an antidepressant with aripiprazole or with bupropion-slow release (SR) vs. switching treatment to bupropion-SR monotherapy on symptom remission in Veterans with Major Depressive Disorder (MDD) who have not achieved optimal response after an adequate trial on antidepressant (a selective serotonin reuptake inhibitor \[SSRI\] or serotonin and norepinephrine reuptake inhibitor \[SNRI\] or mirtazapine) monotherapy. The secondary objectives are to compare the acute (up to 12 weeks) and long term (up to 36 weeks) efficacy, safety, effects on functioning, suicidality, quality of life, anxiety and other associated symptoms, costs and cost-effectiveness of each of the three treatments.


Options:
A: Arm Label: Switching: Bupropion-SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Switching: Bupropion-SR | Arm Label: Augmenting: Antidepressant + Bupropion-SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Augmenting: Antidepressant + Bupropion-SR | Arm Label: Augmenting: Antidepressant + Aripiprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Augmenting: Antidepressant + Aripiprazole | Intervention Type: DRUG; Name: Switching: Bupropion-SR; Assigned to Arm(s): Switching: Bupropion-SR | Intervention Type: DRUG; Name: Augmenting: Antidepressant + Bupropion-SR; Assigned to Arm(s): Augmenting: Antidepressant + Bupropion-SR | Intervention Type: DRUG; Name: Augmenting: Antidepressant + Aripiprazole; Assigned to Arm(s): Augmenting: Antidepressant + Aripiprazole
B: Arm Label: Continue sertraline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline | Arm Label: Augment with mirtazapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline, Drug: Mirtazapine | Arm Label: Switch to mirtazapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mirtazapine | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): Augment with mirtazapine, Continue sertraline | Intervention Type: DRUG; Name: Mirtazapine; Assigned to Arm(s): Augment with mirtazapine, Switch to mirtazapine
C: Arm Label: Duloxetine Hydrochloride (60 mg); Type: EXPERIMENTAL; Interventions: Drug: Duloxetine hydrochloride, Drug: Placebo | Arm Label: Duloxetine Hydrochloride (120 mg); Type: EXPERIMENTAL; Interventions: Drug: Duloxetine hydrochloride, Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine hydrochloride; Assigned to Arm(s): Duloxetine Hydrochloride (120 mg), Duloxetine Hydrochloride (60 mg) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Duloxetine Hydrochloride (120 mg), Duloxetine Hydrochloride (60 mg)
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to citalopram, Drug: Placebo to vilazodone | Arm Label: Vilazodone 20 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone, Drug: Placebo to citalopram, Drug: Placebo to vilazodone | Arm Label: Vilazodone 40 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone, Drug: Placebo to citalopram, Drug: Placebo to vilazodone | Arm Label: Citalopram 40 mg/day; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo to vilazodone, Drug: Citalopram | Intervention Type: DRUG; Name: Vilazodone; Assigned to Arm(s): Vilazodone 20 mg/day, Vilazodone 40 mg/day | Intervention Type: DRUG; Name: Placebo to citalopram; Assigned to Arm(s): Placebo, Vilazodone 20 mg/day, Vilazodone 40 mg/day | Intervention Type: DRUG; Name: Placebo to vilazodone; Assigned to Arm(s): Citalopram 40 mg/day, Placebo, Vilazodone 20 mg/day, Vilazodone 40 mg/day | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): Citalopram 40 mg/day

Answer: A